Infrascan’s handheld scanner landed FDA de novo approval to help first responders detect brain bleeds in patients who have undergone a traumatic head injury.
The Infrascanner Model 1000 uses near-infrared imaging to detect bleeds at an injury site within the "golden hour," the period following head trauma when pre-hospital analysis is critical.
"While patients with suspected brain injuries routinely receive a CT scan, this portable device offers emergency room physicians a non-invasive mechanism to aid in assessing whether an immediate CT scan is needed," Christy Foreman, of the FDA’s Center for Devices & Radiological Health, said in prepared remarks.
The federal watchdog agency approved the Infrascanner through the "de novo" classification process, a pathway designed for low-risk medical devices that can’t be compared to devices currently on the market.
In a 383-patient study, the Philadelphia-based company’s handheld scanner detected nearly 75 percent of brain bleeds detected by a computed tomography scan. When CT scans detected no hematoma, neither did the Infrascanner 82 percent of the time.
The federal watchdog agency stressed that the Infrascanner Model 1000 is not a replacement for a standard CT scan.
St. Jude launches European clinical trials
St. Jude Medical announced the first implant of its Portico transcatheter aortic valve implant in a European trial. The clinical trial will support a bid for CE Mark approval. Read more